How does this compare with the size of other Phase 3 obesity programmes?

It is in the normal range. Berobenatide's VESPER-4 plans 3,578 participants and its diabetes trial 1,044, which is close to the same split. Pivotal obesity programmes run into the thousands because of the safety database expected for chronic dosing in a large population, not because detecting a weight difference is hard.

When will results be available?

Primary completion for both trials is September 2028. Topline reporting typically follows some months after that, and full publication later still. Any figure quoted before then comes from earlier-phase work.

Is aleniglipron the same as orforglipron?

No. Both are oral non-peptide GLP-1 receptor agonists, which is a shared mechanism and a shared administration route, not a shared molecule. Orforglipron is licensed; aleniglipron is investigational, and its Phase 3 evidence does not yet exist.

Why does the registry say triple-masked when the sponsor says double-blind?

The registry field records how many parties are masked - typically participant, care provider, investigator and outcomes assessor in some combination - and 'double-blind' in ordinary usage does not map cleanly onto it. The registry entry is the more precise statement.

Research & Regulatory News

Two Phase 3 Trials, 4,700 Participants, and One Missing Acronym

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

ACCOMPLISH-1 and ACCOMPLISH-2 are the two Phase 3 trials of aleniglipron, an oral non-peptide GLP-1 receptor agonist. Together they plan to enrol 4,700 participants across three maintenance dose arms and placebo, with primary completion for both trials in September 2028.

Key facts

Compound: Aleniglipron (GSBR-1290), oral small-molecule GLP-1 receptor agonist
Sponsor: Structure Therapeutics
ACCOMPLISH-1: NCT07654361, 3,600 participants, obesity or overweight with a comorbidity
ACCOMPLISH-2: NCT07654374, 1,100 participants, obesity or overweight with type 2 diabetes
Design: Randomised, placebo-controlled, triple-masked, four arms
Dose arms: 45 mg, 90 mg, 180 mg or placebo
Titration: 2.5 mg starting dose, 4-week increments
Primary endpoint: Percent change in body weight from baseline
Primary completion: September 2028 for both

What has started

Structure Therapeutics reported in August 2026 that the first patients had been dosed in the Phase 3 ACCOMPLISH programme for aleniglipron. The registry shows two trials. NCT07654361 began on 13 July 2026 and plans 3,600 participants with obesity or overweight and a weight-related comorbidity. NCT07654374 began on 17 July 2026 and plans 1,100 participants with obesity or overweight and type 2 diabetes. Both are recruiting, both are triple-masked and placebo-controlled, and both carry percent change in body weight from baseline as the primary endpoint with primary completion in September 2028.

The design, stated as registered

Each trial randomises to one of four arms: three maintenance doses of aleniglipron or placebo. The company describes those doses as 45 mg, 90 mg and 180 mg, with treatment beginning at a 2.5 mg starting dose and increasing in four-week increments. A starting dose seventy-two times below the highest maintenance dose is a substantial titration ladder, and it is the standard answer to the gastrointestinal tolerability problem that defines this class. These are dose arms in registered trials conducted under clinical supervision and are recorded here as facts about the trials.

The acronym is in one record and not the other

NCT07654374's official title ends '(ACCOMPLISH-2)'. Its structured acronym field is empty. NCT07654361 - the larger and, for a weight-management indication, more consequential of the two - carries the ACCOMPLISH name in neither its acronym field nor its official title, whose text is purely descriptive. So the trial that most coverage will refer to as ACCOMPLISH-1 cannot be found in the registry by that name at all. This is now a documented pattern rather than an isolated slip: the same thing occurs across the VESPER programme for a different sponsor, where two Phase 3 records similarly carry press-attributed names the registry does not hold.

Why the omission has practical consequences

Registry search matches structured fields. A trial acronym that lives only in press releases, or only in free-text title, does not surface when someone tries to check a claim attached to that name. The downstream effect is that readers who try to verify a statement about ACCOMPLISH-1 find nothing, and reasonably conclude either that the trial does not exist or that they have searched wrong. The reliable route is always the same: find the NCT number and verify against that, because the NCT number is the only identifier guaranteed to be unique, stable and searchable.

What the programme is testing that the Phase 2 work could not

Aleniglipron's Phase 2 data is encouraging and small. ACCESS enrolled 230 adults over 36 weeks and ACCESS II enrolled 85 over 44 weeks. The step to 3,600 and 1,100 participants over a longer horizon is what pivotal evidence requires, and the reasons are as much about safety as efficacy - a chronically dosed weight-management drug needs an exposure database large enough to characterise uncommon events. The separate diabetes trial matters too: efficacy in weight management and efficacy on glycaemic control in people with type 2 diabetes are different claims requiring different evidence, and running them in parallel is how a sponsor supports both.

What this does not mean

Aleniglipron is investigational. It is not licensed in any jurisdiction, it is not available on prescription, and it is not supplied on this site in any form. Starting Phase 3 is a statement about a development programme, not about efficacy or safety; the trials exist because the questions are open. Anyone considering treatment for obesity should be discussing licensed options with a clinician, and research material is never an alternative to a licensed medicine.

Quick reference

	ACCOMPLISH-1	ACCOMPLISH-2
Registration	NCT07654361	NCT07654374
Acronym in registry	Nowhere	Official title only
Planned enrolment	3,600	1,100
Population	Obesity/overweight with comorbidity	Obesity/overweight with type 2 diabetes
Start date	13 July 2026	17 July 2026
Primary completion	September 2028	September 2028

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How does this compare with the size of other Phase 3 obesity programmes?: It is in the normal range. Berobenatide's VESPER-4 plans 3,578 participants and its diabetes trial 1,044, which is close to the same split. Pivotal obesity programmes run into the thousands because of the safety database expected for chronic dosing in a large population, not because detecting a weight difference is hard.
When will results be available?: Primary completion for both trials is September 2028. Topline reporting typically follows some months after that, and full publication later still. Any figure quoted before then comes from earlier-phase work.
Is aleniglipron the same as orforglipron?: No. Both are oral non-peptide GLP-1 receptor agonists, which is a shared mechanism and a shared administration route, not a shared molecule. Orforglipron is licensed; aleniglipron is investigational, and its Phase 3 evidence does not yet exist.
Why does the registry say triple-masked when the sponsor says double-blind?: The registry field records how many parties are masked - typically participant, care provider, investigator and outcomes assessor in some combination - and 'double-blind' in ordinary usage does not map cleanly onto it. The registry entry is the more precise statement.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum